Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

Tecentriq meanwhile is gathering pace after a slow start on the back of new indications, including lung and breast cancer, and looks set to break the blockbuster threshold this year as ... With Roche’s pipeline set to deliver approvals some more

Latest news

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    trials being conducted in gastric, colorectal, and non-small cell lung cancer (NSCLC). ... The ADC rounds out AZ’s portfolio of emerging cancer drugs, sitting alongside cancer immunotherapy Imfinzi (durvalumab), targeted therapy Tagrisso for lung

  • NICE green light for Imfinzi in groundbreaking early lung cancer treatment NICE green light for Imfinzi in groundbreaking early lung cancer treatment

    Early treatment opens up possibility of cure. AstraZeneca's immunotherapy Imfinzi has been recommended by NICE for patients with stage 3 non-small cell lung cancer (NSCLC). ... we’ve seen for a number of years in treating locally advanced non-small

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    It will be applied across all eight of Keytruda’s monotherapy indications in five tumour types, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, head and neck cancer and ... It made history by becoming the first FDA-approved drug

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    This is a meaningful treatment advance as an anti-PD-1 combination therapy is now approved in Europe for this type of non-small cell lung cancer. ... With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    At the American Association for Cancer Research (AACR) Meeting in Atlanta, US, AZ intends to address Imfinzi’s latest setback as a first-line therapy in metastatic non-small cell lung ... Those who express a high TMB could carry more markers on the

More from news
Approximately 1 fully matching, plus 538 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • Therapy Watch expands its oncology portfolio

    This month  Therapy Watch  Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),

  • How pembrolizumab will change the management of advanced lung cancer

    The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics